PECAM-1 Targeted Nanoprobe For Early CRS Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating cytokine release syndrome (CRS) associated with CAR-T cell immunotherapy lack objective indicators and effective monitoring tools, making it difficult to classify and intervene early in the condition.
Innovation Solution
A PECAM-1-targeted nanoprobe is developed, specifically a radionuclide-labeled nanoprobe (αPECAM-1-AT@HCNPs) that targets PECAM-1, allowing for early detection and intervention by loading antithrombin to inhibit coagulation activation and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical manifestations are used to determine CRS grading, then diagnosis can be made based on observable symptoms, but objective indicators for early detection and quantification are lacking
Solution Approach 1:
The nanoprobe is designed to detect PECAM-1 on activated endothelial cells before severe CRS symptoms manifest. By targeting early molecular changes in the endothelium that precede full-blown CRS, the system enables preliminary detection and intervention before the condition progresses to severe stages requiring intensive treatment
Solution Approach 2:
The patent replaces traditional mechanical/clinical assessment methods with molecular imaging technology. Instead of relying on physical examination and symptom observation, the system uses radionuclide-labeled nanoprobles that bind to PECAM-1 biomarkers, enabling objective, quantifiable measurement of endothelial activation through nuclear medicine imaging
2Measurement precision
If common cytokine monitoring processes are used, then cytokine levels can be measured, but the indicators appear later and thresholds are difficult to quantify
Solution Approach 1:
The nanoprobe detects PECAM-1 expression on endothelial cells before cytokine levels rise to detectable thresholds. Since PECAM-1 upregulation occurs early in the CRS pathway as endothelial cells become activated, this provides a leading indicator that precedes the cytokine storm by hours or days, enabling earlier intervention
Solution Approach 2:
The patent uses PECAM-1 as an intermediary biomarker that connects endothelial activation to subsequent cytokine release. Rather than measuring cytokines directly, the system detects PECAM-1 on endothelial cells, which serves as an upstream marker that reliably predicts impending cytokine release and CRS development
3Measurement precision
If radionuclide-labeled nanoprobe is used for targeting, then early molecular markers can be detected, but the preparation process becomes complex
Solution Approach 1:
The nanoprobe preparation is divided into distinct modular steps: (1) synthesis of HYNIC-labeled 4G6 antibody, (2) radiolabeling with 68Ga or 177Lu, (3) quality control and purification. Each module can be independently optimized and validated, making the complex process manageable and reproducible in clinical settings
Solution Approach 2:
The patent optimizes radiolabeling parameters including pH (5.5-6.5), temperature (room temperature to 37°C), incubation time (30-60 minutes), and antibody-to-radionuclide ratio to maximize labeling efficiency while minimizing background noise. These parameter optimizations reduce the need for complex purification steps and improve overall process efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoprobe enables early monitoring and intervention of CRS by accurately targeting microvascular imaging and releasing antithrombin in localized areas, effectively reducing inflammation and coagulation activation, thus providing a novel diagnostic and therapeutic approach.
Implementation Method 1
subjecting hydrazinonicotinamide (HYNIC) and PECAM-1-4G6 to a reaction in an acidic environment, and filtering a resulting reaction product to allow a reaction with a radionuclide lotion in the presence of a reducing agent to obtain the radionuclide-labeled PECAM-1_4G6 mAb
Implementation Method 2
dissolving the αPECAM-1-HCNPs and antithrombin in an equal proportion, such that the antithrombin is adsorbed and loaded onto the αPECAM-1-HCNPs through an electrostatic interaction
Data Source
AI summary
The present disclosure provides a platelet endothelial cell adhesion molecule-1 (PECAM-1)-targeted nanoprobe for integrated diagnosis and treatment, and a preparation method and use thereof. The preparation method includes the following steps: preparation of radionuclide-labeled PECAM-1_4G6 mAb: subjecting hydrazinonicotinamide (HYNIC) and PECAM-1-4G6 to a reaction in an acidic environment, and filtering a resulting reaction product to allow a reaction with a radionuclide lotion in the presence of a reducing agent to obtain the radionuclide-labeled PECAM-1_4G6 mAb; and preparation of αPECAM-1-AT@HCNPs: adding N,N′-disuccinimidyl carbonate (DSC) into an aqueous solution of HES-CH nanoparticles (HCNPs), mixing evenly, conducting dialysis, and adding the radionuclide-labeled PECAM-1_4G6 mAb to allow a reaction at a room temperature to obtain an aqueous solution of αPECAM-1-HCNPs; and dissolving the αPECAM-1-HCNPs and antithrombin in an equal proportion, such that the antithrombin is adsorbed and loaded onto the @PECAM-1-HCNPs through an electrostatic interaction, and conducting purification to obtain the @PECAM-1-AT@HCNPs.